

EXPANDED ACCESS POLICY

Frontier Medicines Corporation (“Frontier”) is a clinical-stage precision medicines company focused on developing innovative and clinically differentiated therapies to patients with serious and life-threatening conditions. To help us realize this mission, we are privileged to collaborate with clinical investigators and patients to conduct the clinical trials necessary to assess the safety and efficacy of our investigational drug products and seek required regulatory approval by the U.S. Food and Drug Administration (FDA) and other countries’ health authorities.

Until an investigational drug product, including Frontier’s candidates, receives regulatory approval, patient access to investigational treatments is generally restricted to participation in clinical trials. We believe this approach best serves patients by ensuring the potential benefit to patients outweighs the possible risks. In some circumstances, when a patient is not eligible to participate in a clinical trial and may not have options for alternative therapies, a patient’s doctor may attempt to seek special access to an investigational drug product for that patient through what’s known as an expanded access or compassionate use program supported by a clinical trial sponsor, such as Frontier. The primary purpose for expanded access or compassionate use is to use the investigational drug for patient treatment purposes, rather than to gather data on safety, tolerability and effectiveness.

While Frontier’s ultimate goal is to support patients, patient families and the patient communities by providing broad access to our investigational drug products as quickly as possible, we believe that access to our investigational drug products should be limited to controlled clinical trials until such time as their safety and tolerability have been confirmed and dose and dosing regimen optimized.

As such, currently, Frontier does not offer an expanded access or compassionate use program as we believe participation in our clinical trials is the most safe and appropriate way for patients to access our investigational drug products. We will continue to evaluate the possibility of expanded access and update our policy if our position changes. For information regarding Frontier-sponsored clinical trials, please visit www.clinicaltrials.gov and search for Frontier Medicines Corporation. Should patients or healthcare providers require additional information about the status of our investigational therapies, please do not hesitate to contact Frontier Medicines Corporation at clinicaltrials@frontiermeds.com.